GlassScriptPhysician profile
Erin E Richardson
NPI 1447519038
$2,887.04
in general payments reported to CMS, 2019-2025
26 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.69 · 2020: $12.06 · 2022: $397 · 2023: $550 · 2024: $801 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,444.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $505.84 | 2019-2025 | |
| Ascendis Pharma Endocrinology INC | $383.20 | 2022-2025 | Skytrofa |
| Novo Nordisk INC | $294.98 | 2019-2025 | Sogroya, Wegovy |
| Neurocrine Biosciences, INC. | $260.24 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $181.52 | 2022-2025 | Strensiq |
| Biomarin Pharmaceutical INC. | $124.81 | 2022-2025 | Voxzogo 1.2mg |
| Sanofi-Aventis U.S. LLC | $122.07 | 2022-2024 | |
| Tolmar, INC. | $103.56 | 2023-2025 | Fensolvi |
| Beta Bionics, INC. | $103.15 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Xeris Pharmaceuticals, INC. | $101.16 | 2022-2024 | Gvoke Hypopen |
| Pfizer INC. | $97.45 | 2024-2025 | |
| Kyowa Kirin, INC. | $95.12 | 2023-2025 | Crysvita |
| Eton Pharmaceuticals, INC. | $73.02 | 2023-2024 | Alkindi |
| Insulet Corporation | $69.55 | 2022-2024 | Omnipod |
| Tandem Diabetes Care, INC. | $63.86 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $54.29 | 2022 | |
| Abbott Laboratories | $45.53 | 2024-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $36.84 | 2024-2025 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $36.12 | 2023 | Triptodur |
| Ultragenyx Pharmaceutical INC. | $27.81 | 2022-2023 | |
| Soleno Therapeutics, INC. | $22.92 | 2025 | Vykat Xr |
| E.R. Squibb & Sons, L.L.C. | $19.34 | 2025 | Cobenfy |
| Medtronic, INC. | $17.13 | 2025 | Minimed 780g |
| Rhythm Pharmaceuticals, INC. | $16.80 | 2025 | Imcivree |
| Endo USA, INC. | $16.79 | 2025 | Supprelin |
| Endo Pharmaceuticals INC. | $13.94 | 2024 | Supprelin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.